Ruth Ruddle
Institute of Cancer Research(GB)Cancer Research UK(GB)Cancer Research UK Clinical Trials Unit(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Computational Drug Discovery Methods, Cancer-related gene regulation, Lung Cancer Treatments and Mutations, Ovarian cancer diagnosis and treatment
Most-Cited Works
- → Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease(2014)207 cited
- → Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo(2013)150 cited
- → Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers(2020)130 cited
- → ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma(2019)118 cited
- → Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance(2023)112 cited
- → A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription(2010)103 cited